[Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor].
Gan To Kagaku Ryoho
; 50(12): 1307-1310, 2023 Dec.
Article
en Ja
| MEDLINE
| ID: mdl-38247069
ABSTRACT
Necitumumab enhances antitumor immunity by decreasing the PD-L1 expression; it is expected to improve the prognosis of patients treated with an immune checkpoint inhibitor(ICI)by inhibiting the IL-8 expression. Since the combined effect of necitumumab and PD-L1 inhibitor was confirmed in an in vivo study conducted in transgenic mice, further antitumor effects can be expected by the combined use of necitumumab and ICI.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Anticuerpos Monoclonales Humanizados
/
Inhibidores de Puntos de Control Inmunológico
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Año:
2023
Tipo del documento:
Article